Journal Watch · Frontiers in Immunology · 2026

The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis.

Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.

Li X, Tang L, Cao J, Liu YFrontiers in Immunology3 min readPharma relevance 60/100

DOI: 10.3389/fimmu.2026.1753670PMID: 42051493Study type: review / perspective

TL;DR

Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.

Key findings

  • The pyruvate metabolism-based signature predicted prognosis effectively.
  • Combination therapy with (R)-GNE-140 and PD-1 blockade inhibited Huh7 proliferation, migration, and xenograft tumor growth without liver or renal toxicity.<h4>Conclusion</h4>ICI therapy induces metabolic remodeling in HCC, marked by pyruvate metabolism dysregulation and lactate accumulation, contributing to resistance.
  • Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.

What they did

Key transcription factors (MYC, SP5, HLF, SREBF1) were identified. CellChat revealed enhanced SPP1-CD44 and APOA1-ABCA1 signaling. Pseudotime analysis indicated terminal hepatocyte differentiation.

Full abstract (original)

Background: <h4>Objective</h4>To investigate metabolic reprogramming-especially pyruvate metabolism-in hepatocellular carcinoma (HCC) before and after immune checkpoint inhibitor (ICI) therapy, construct a metabolism-related prognostic model, and evaluate the therapeutic potential of targeting LDHA.<h4>Methods</h4>Integrated single-cell RNA-seq data (GEO, Mendeley) were analyzed using Seurat, AUCell, pySCENIC, CellChat, and Monocle. A prognostic model was developed from TCGA data by Cox and Lasso regression. Functional validation included <i>in vitro</i> CCK8 and Transwell assays in Huh7 cells and <i>in vivo</i> xenograft experiments combining the LDHA inhibitor (R)-GNE-140 with a PD-1 antibody.<h4>Results</h4>Post-ICI, HCC cells upregulated pyruvate metabolism genes (LDHA, LDHB, LDHD) but showed decreased glycolysis, lactate buildup, reduced acetylation, and suppressed TCA cycle with AMPK activation.

What they did: Key transcription factors (MYC, SP5, HLF, SREBF1) were identified. CellChat revealed enhanced SPP1-CD44 and APOA1-ABCA1 signaling. Pseudotime analysis indicated terminal hepatocyte differentiation.

Results & conclusions: The pyruvate metabolism-based signature predicted prognosis effectively. Combination therapy with (R)-GNE-140 and PD-1 blockade inhibited Huh7 proliferation, migration, and xenograft tumor growth without liver or renal toxicity.<h4>Conclusion</h4>ICI therapy induces metabolic remodeling in HCC, marked by pyruvate metabolism dysregulation and lactate accumulation, contributing to resistance. Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1753670 · PubMed 42051493.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. Key transcription factors (MYC, SP5, HLF, SREBF1) were identified.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1753670. PubMed ID: 42051493. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Li X, Tang L, Cao J, Liu Y. The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1753670.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-inhibitory-effect-of-hepatic-cancer-energy-metabolism-on-immune-chec-753670/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides